JP2006525368A5 - - Google Patents

Download PDF

Info

Publication number
JP2006525368A5
JP2006525368A5 JP2006514250A JP2006514250A JP2006525368A5 JP 2006525368 A5 JP2006525368 A5 JP 2006525368A5 JP 2006514250 A JP2006514250 A JP 2006514250A JP 2006514250 A JP2006514250 A JP 2006514250A JP 2006525368 A5 JP2006525368 A5 JP 2006525368A5
Authority
JP
Japan
Prior art keywords
ligand
lipid
alkyl
independently
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006514250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/013727 external-priority patent/WO2004098524A2/en
Publication of JP2006525368A publication Critical patent/JP2006525368A/ja
Publication of JP2006525368A5 publication Critical patent/JP2006525368A5/ja
Pending legal-status Critical Current

Links

JP2006514250A 2003-05-02 2004-05-03 脂質白金錯体およびその使用方法 Pending JP2006525368A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46756703P 2003-05-02 2003-05-02
PCT/US2004/013727 WO2004098524A2 (en) 2003-05-02 2004-05-03 Lipid platinum complexes and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2006525368A JP2006525368A (ja) 2006-11-09
JP2006525368A5 true JP2006525368A5 (enExample) 2007-06-14

Family

ID=33435089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006514250A Pending JP2006525368A (ja) 2003-05-02 2004-05-03 脂質白金錯体およびその使用方法

Country Status (6)

Country Link
US (1) US20070160656A1 (enExample)
EP (1) EP1622585A4 (enExample)
JP (1) JP2006525368A (enExample)
AU (1) AU2004235781A1 (enExample)
CA (1) CA2524478A1 (enExample)
WO (1) WO2004098524A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050425A1 (en) * 2003-05-20 2008-02-28 Jonathan Lewis Combination Chemotherapy Comprising 5-Fluorouracil or a Derivative Thereof and a Liposomal Platinum Complex
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
AU2005228410A1 (en) 2004-03-29 2005-10-13 University Of South Florida Effective treatment of tumors and cancer with triciribine and related compounds
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
WO2008070136A1 (en) * 2006-12-06 2008-06-12 University Of South Florida Compositions including triciribine and one or more platinum compounds and methods of use thereof
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
AU2010255391C1 (en) * 2009-06-03 2016-10-27 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
SG185722A1 (en) 2010-06-04 2013-01-30 Univ Ohio Phosphaplatins and their use for treatment of cancers
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CN103665050B (zh) * 2013-08-29 2016-04-27 西北工业大学 一种苯基咪唑邻菲罗啉竹红菌素铂配合物及其制备方法
WO2017001625A1 (en) 2015-06-30 2017-01-05 Sequessome Technology Holdings Limited Multiphasic compositions
CN105481902B (zh) * 2015-12-03 2017-12-05 昆明贵金属研究所 以磷酸二氢根为轴向配体的铂(iv)抗癌化合物
CN113453667A (zh) * 2018-11-02 2021-09-28 利帕克肿瘤学有限责任公司 脂质体增强腹腔内化学疗法
WO2021043402A1 (en) * 2019-09-05 2021-03-11 Vuab Pharma A.S. New platinum iv complexes with substantially increased antitumor efficacy
ES2998498T3 (en) * 2020-03-10 2025-02-20 Univ Chung Yuan Christian Liposome composition and preparation method thereof
WO2021216849A1 (en) * 2020-04-22 2021-10-28 Oncovolution, Llc Peptide platinum complexes and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5829957B2 (ja) * 1977-09-12 1983-06-25 喜徳 喜谷 新規な白金錯体
JPS5622724A (en) * 1979-08-02 1981-03-03 Asahi Chem Ind Co Ltd Pharmaceutical preparation of n4-acylcytosine arabinoside
EP0113508A1 (en) * 1982-11-04 1984-07-18 Inco Research & Development Center, Inc. Hydrophobic platinum compounds and their preparation
US5041581A (en) * 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5384127A (en) * 1985-10-18 1995-01-24 Board Of Regents, The University Of Texas System Stable liposomal formulations of lipophilic platinum compounds
US5117022A (en) * 1985-10-18 1992-05-26 The Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
WO1998024424A1 (en) * 1996-12-03 1998-06-11 Rijksuniversiteit Utrecht Cisplatinum comprising pharmaceutical
US5843475A (en) * 1996-12-06 1998-12-01 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes
CN1191067C (zh) * 1997-02-05 2005-03-02 法玛西雅厄普约翰美国公司 高不溶性铂配合物的脂质复合物和脂质体
JP5096657B2 (ja) * 2000-08-11 2012-12-12 大日本住友製薬株式会社 シスプラチン耐性癌治療剤
AU2003258075A1 (en) * 2002-08-06 2004-02-23 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases

Similar Documents

Publication Publication Date Title
JP2006525368A5 (enExample)
JP2005528325A5 (enExample)
JP2017538677A5 (enExample)
JP2005511699A5 (enExample)
JP2006519852A5 (enExample)
JP2019512478A5 (enExample)
JP2014510729A5 (enExample)
JP2009504763A5 (enExample)
JP2019515908A5 (enExample)
JP2004533444A5 (enExample)
JP2006151984A5 (enExample)
JP2015512860A5 (enExample)
JP2002517491A5 (enExample)
JP2018135343A5 (enExample)
JP2016503414A5 (enExample)
JP2020530007A5 (enExample)
JP2013538213A5 (enExample)
JP2014523413A5 (enExample)
JP2020514344A5 (enExample)
JPWO2020173935A5 (enExample)
JP2004502684A5 (enExample)
JP2014516075A (ja) 癌治療のためのメタロセン化合物の使用
JP2010539091A5 (enExample)
RU2002105374A (ru) Сочетанная терапия с использованием пентафторбензолсульфонамидов
JP2018525447A5 (enExample)